Related Experiment Video
Updated: Jul 31, 2026

Two- and Three-Dimensional Live Cell Imaging of DNA Damage Response Proteins
Published on: September 28, 2012
p53 binds to cisplatin-damaged DNA
1Wright State University, Department of Biochemistry and Molecular Biology, 3640 Colonel Glenn Hyw, Dayton, OH 45435, USA.
Abstract:
We have previously shown that bacterially expressed p53 protein or p53 protein isolated from cis-diamminedichloroplatinum II (cisplatin)-damaged cells is capable of binding to double-stranded platinated DNA molecules lacking any p53 DNA binding sites. Here we report using various p53 mutants that two separate domains of p53 protein affect p53 binding to platinated DNA. Mutations within the central core of p53, the domain responsible for sequence-specific DNA binding activity, completely eliminated p53 binding to platinated DNA. Based on competition experiments p53 preferred binding to sequence-specific DNA molecules over platinated DNA molecules. However, p53 binding to platinated DNA molecules was significantly stronger than p53 interactions with DNA molecules lacking damage and a p53 consensus site. Finally, an antibody specific to the C-terminal domain of p53 (pAb421) which activates sequence-specific DNA binding activity inhibited p53 binding to platinated DNA. Taken together, these results suggest that in addition to binding to p53 DNA binding sites, p53 also interacts with cisplatin-damaged DNA molecules.
Insights
The tumor suppressor protein p53 binds to DNA damaged by cisplatin, independent of its usual DNA binding sites. This interaction involves specific p53 domains and is stronger than binding to undamaged DNA.
Area of Science:
- Molecular Biology
- Cancer Research
- Biochemistry
Background:
- The p53 protein is a crucial tumor suppressor involved in DNA repair and cell cycle control.
- Previous studies demonstrated p53 binding to DNA damaged by cisplatin, even without specific binding sites.
- The precise mechanisms and domains of p53 involved in this interaction remained unclear.
Purpose of the Study:
- To investigate the specific domains of p53 protein responsible for binding to cisplatin-damaged DNA.
- To characterize the binding affinity of p53 to platinated DNA compared to undamaged DNA.
- To elucidate the role of p53's DNA-binding and C-terminal domains in interacting with damaged DNA.
Main Methods:
- Utilized various p53 mutants to assess the impact of domain-specific alterations on DNA binding.
- Performed competition experiments to compare p53 binding preferences between platinated and sequence-specific DNA.
- Employed an antibody (pAb421) targeting the C-terminal domain to evaluate its effect on p53-DNA interactions.
Main Results:
- Mutations in p53's central core domain abolished binding to platinated DNA.
- p53 demonstrated a preference for sequence-specific DNA over platinated DNA in competition assays.
- Binding of p53 to cisplatin-damaged DNA was significantly stronger than to undamaged DNA lacking a consensus site.
- An antibody targeting the C-terminal domain inhibited p53 binding to platinated DNA.
Conclusions:
- Two distinct domains of the p53 protein are critical for its interaction with cisplatin-damaged DNA.
- p53 exhibits a dual mode of DNA interaction, binding to both specific sites and damaged DNA structures.
- These findings suggest a broader role for p53 in recognizing and responding to DNA damage beyond canonical sequence recognition.
Related Concept Videos
Negative Regulator Molecules
Overview of DNA Repair
Chemically...
DNA Damage can Stall the Cell Cycle
Homologous Recombination
Abnormal Proliferation
DNA Damage Can Stall the Cell Cycle

